Provides a review of the mechanisms and current status of antithrombotic therapies, including antiaggregants, anticoagulants, and thrombolytics, for acute heart attacks.
Updates clinicians on antithrombotic options for acute MI; leaves open optimal regimen selection in evolving practice.
Pharmacologic candidates for prophylaxis and therapy against coronary thrombosis include platelet antiaggregants, anticoagulants, and thrombolytic agents. As understanding of the mechanisms of thrombogenesis and thrombolysis increases, so does the ability to anticipate when and how these agents can be expected to be effective. Current trials of the thrombolytic agents are viewed in this context.
No takes yet. Share an insight, caveat, or question.
Sol Sherry (1972) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: